Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01831193|
Recruitment Status : Completed
First Posted : April 15, 2013
Last Update Posted : July 24, 2014
|Condition or disease||Intervention/treatment||Phase|
|Proteinuria||Drug: Curcumin||Phase 3|
Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L.
Different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments.
This compound acts as a bifunctional antioxidant:
ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through Keap1/Nrf2/ARE pathway.
Although RAAS blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease.
Due to the low cost and few side effects of curcumin, this could become an adjuvant treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney disease.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease|
|Study Start Date :||February 2013|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||April 2014|
|Active Comparator: Diabetic||
Other Name: Turmeric
|Active Comparator: Non-diabetic||
Other Name: Turmeric
- Change in proteinuria [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01831193
|Instituto Nacional de Cardiologia Ignacio Chavez|
|Mexico city, DF, Mexico, 14080|